Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
BACKGROUND
Diabetic nephropathy is the primary cause of end-stage renal disease (ESRD), which involves substantial economic burden. The primary objective of this study was to estimate the potential effect of losartan on the costs associated with ESRD in patients with diabetic nephropathy in a Greek setting. A secondary aim was to approximate the direct health care cost of renal replacement therapy (RRT) in Greece.


METHODS
A cost-effectiveness analysis was performed to compare losartan with placebo in patients with type 2 diabetes and nephropathy. Clinical data were derived from the RENAAL study. All costs were calculated from the perspective of the Greek social insurance system, in 2003 euros. Future costs were discounted at 3%. The time horizon was 3.5 years. Extensive sensitivity analyses were performed.


RESULTS
The reduction in the number of ESRD days over 3.5 years in patients treated with losartan reduced ESRD-related costs by 3,056.54 euros, resulting in net cost savings of 1,665.43 euros per patient. Net cost savings increase thereafter, increasing to 2,686.48 euros per patient over a period of 4.0 years. The results were robust under a wide range of plausible assumptions. The weighted mean daily cost of RRT was estimated at 90.97 euros per patient. The total economic burden of RRT for the year 2003 has been estimated at 304.773 million euros.


CONCLUSIONS
This study demonstrated that treatment of patients with diabetic nephropathy in Greece with losartan is cost-effective, as it leads to important savings for the social insurance system by slowing the progression to ESRD.
Stafylas
P C
PC
First Department of Medicine, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece.
Sarafidis
P A
PA
Lasaridis
A N
AN
Tsakni
E
E
Niakas
D A
DA
Dombros
N V
NV
Grekas
D M
DM
Bakris
G L
GL
D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000191:economics; D006115:Greece; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000191:economics; D019808:Losartan / Q000191:economics / Q000627:therapeutic use*; D009313:National Health Programs
D047228:Angiotensin II Type 1 Receptor Blockers; D019808:Losartan